[18F]-FET and [18F]-FAZA PET guided irradiation of glioblastoma in rats by Verhoeven, Jeroen et al.
[18F]-FET	and	[18F]-FAZA	PET	guided	irradiation	of	glioblastoma	in	rats	
	
J.	Verhoeven1,	J.	Bolcaen2,	B.	Descamps3,	T.	Baguet1,	G.	Hallaert4,	K.	Kersemans2,	T.	
Boterberg5,	K.	Deblaere6,	C.	Vanhove3,	F.	De	Vos1,	I.	Goethals2		
	
1	Ghent	University,	Lab	for	Radiopharmacy,	Ghent,	Belgium	
2	Ghent	University	Hospital,	Department	of	Nuclear	Medicine,	Ghent,	Belgium	
3	iMinds-IBiTech-MEDISIP	Ghent	University,	Department	of	Electronics	and	Information	Systems,	Ghent,	
Belgium	
4	Ghent	University	Hospital,	Department	of	Neurosurgery,	Ghent,	Belgium	
5	Ghent	University	Hospital,	Department	of	Radiation	Oncology,	Ghent,	Belgium	
6	Ghent	University	Hospital,	Department	of	Radioloy	and	Medical	Imaging,	Ghent,	Belgium		
	
Introduction	
	
Glioblastoma	(GB)	is	the	most	common	primary	malignant	brain	tumor	of	the	central	nervous	
system1.	 The	 standard	 therapy	 consists	 of	 maximal	 possible	 surgical	 resection	 with	
concomitant	radiation	(RT)	and	chemotherapy.	An	accurate	definition	of	the	tumor	volume	is	
of	utmost	importance	for	guiding	radiation	therapy.	Currently	the	target	volume	delineation	
is	 based	 on	 CT	 and	MRI2,3.	 In	 this	 project	 we	 investigated	 the	 feasibility	 of	 incorporating	
[18F]FET	 and	 [18F]-FAZA	 for	 guiding	 RT	 and	 the	 impact	 on	 treatment	 outcome	 by	 applying	
subvolume	boosting	to	a	PET-defined	tumor	part.	
	
Methods	
	
F98	GB	cells	 inoculated	 in	 the	 rat	brain	were	 imaged	using	T2-	and	contrast-enhanced	T1-
weighted	(CE-T1w)	MRI.	After	tumor	growth,	a	30	min	[18F]-FET	(30min	p.i.)	or	[18F]-FAZA	(2h	
p.i.)	 PET	was	 acquired.	 Subsequently,	 a	 treatment	 planning	 CT	was	 obtained	on	 the	 small	
animal	radiation	research	platform	(SARRP).	A	dose	of	20	Gy	(3x3	mm)	was	delivered	to	the	
target	volume	delineated	based	on	CE-T1w-MRI	(group	1-3).	In	group	2	and	3	an	additional	
radiation	boost	of	5	Gy	(1x1	mm)	was	delivered	to	the	region	with	maximal	PET	tracer	uptake.	
Temozolomide	(TMZ,	5	mg	i.p.)	was	administered	in	groups	1-3	on	five	consecutive	days.	The	
4th	 group	 received	 sham	 injections	 with	 saline.	 Tumor	 volumes	 on	 follow-up	 MRI	 were	
determined	by	drawing	volumes	of	interest	around	the	tumor	on	CE-T1w-MRI	(PMOD).	
	
Results	
	
CE-T1w-MRI	showed	a	heterogeneous	tumor,	enabling	to	select	the	MRI	target	volume.	Both	
[18F]-FET	 and	 [18F]-FAZA	 showed	 an	 increased	 tumor	 uptake.	 After	 co-registration	 of	 the	
planning	CT	with	the	CE-T1w-MRI	and	PET	images,	PET-guided	RT	was	performed.	Using	three	
non-coplanar	arcs,	the	dose	delivered	to	the	normal	surrounding	brain	tissue	was	minimized.	
The	 average,	minimum	and	maximum	dose,	 as	well	 as	 the	D90-,	 D50-	 and	D2-	 values	were	
calculated	 for	 nine	 rats	 with	 both	 RT	 plans.	 The	 dose	 volume	 histograms	 (DVH)	 are	
represented	 in	figure	1.	A	slight	shift	to	the	right	for	the	graph	could	be	noted	of	the	DVH	
based	on	the	RT	with	PET	based	subvolume	boosting.	The	evolution	of	the	normalized	tumor	
volumes	 is	 shown	 in	 figure	2.	Significant	differences	were	 found	between	the	 therapy	and	
control	 groups.	 No	 significant	 differences	 were	 observed	 between	 the	 different	 therapy	
groups.	
	
Conclusions	
	
MRI	guided	irradiation	with	PET	subvolume	boosting	is	feasible,	but	very	labor-intensive.	Tools	
for	faster	and	more	accurate	image	co-registration	would	be	helpful.	Based	on	tumor	growth,	
a	 significant	 difference	 was	 found	 between	 therapy	 and	 no	 therapy,	 but	 no	 significant	
difference	could	be	observed	between	the	three	treatment	groups.	Additional	 information	
from	molecular	 imaging	 techniques	enables	 the	visualization	of	metabolically	highly	active	
regions.	As	GB	are	highly	heterogeneous	solid	tumors,	the	concept	of	biological	target	volume	
and	multidimensional	conformal	RT	seems	promising.	
	
	
Figure	1:	Indication	of	the	overlapping	volume	of	the	three	rotating	bundles	(green,	A).	Dose	volume	histogram	with	isocenter	
based	on	the	center	of	the	gadolinium	containing	contrast	uptake	on	the	T1-weighted	MRI	(B).	Dose	volume	histogram	with	
the	second	isocenter	based	on	the	hot	spot	showed	by	the	PET	scan	(C).		
	
	
Figure	2:	Graphical	representation	of	the	median	change	of	the	tumor	volume	by	day.		
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